Key Takeaways
- Three top Oklo executives collectively offloaded more than $21 million worth of shares on April 1, executing pre-planned transactions through Rule 10b5-1 arrangements.
- CEO Jacob DeWitte has maintained a consistent selling pattern beginning in January, liquidating shares at price points from approximately $112 down to the low $50s.
- Television personality Jim Cramer dismissed Oklo as lacking “prospects for making any money any time in the future” and characterized it as “not a commercial enterprise.”
- The nuclear energy company’s recent quarterly results showed a loss per share of -$0.27, significantly worse than Wall Street’s projection of -$0.17.
- Wall Street maintains a “Moderate Buy” stance with an $84.30 average price target, though multiple analysts have lowered their outlooks recently.
On April 1, 2026, three senior leaders at Oklo executed stock sales exceeding $21 million combined, all conducted through previously established Rule 10b5-1 trading arrangements.
Company CEO and founder Jacob DeWitte liquidated shares at weighted average prices spanning $48.41 to $51.20, generating proceeds of $10,069,852. Following this transaction, DeWitte maintains direct ownership of 691,533 Class A shares, plus indirect control of more than 20 million additional shares.
Co-founder and Chief Operating Officer Caroline Cochran executed an identical dollar-value sale of $10,069,852, with her shares selling between approximately $47.99 and $51.79. Her direct shareholding stands at 658,039 shares post-transaction.
Chief Financial Officer Richard Bealmear participated as well, disposing of 16,342 shares at $51.08 each for total proceeds of $834,749. Bealmear continues to hold 386,008 Class A shares directly.
These transactions were all executed under 10b5-1 trading plans, regulatory mechanisms designed to shield executives from insider trading allegations by establishing predetermined sale schedules.
However, DeWitte’s April 1 activity represents just one chapter in an ongoing divestment campaign. Since January, the CEO has systematically sold shares at various price levels, including transactions near $112, $75, and $63 per share. His cumulative sales over recent months have generated tens of millions in personal proceeds.
The April 1 transaction alone—encompassing 200,000 shares across two separate sales—decreased his direct ownership position by 17.58%.
Cramer’s Harsh Assessment
These executive sales coincide with sharp criticism from CNBC’s Jim Cramer. Responding to a viewer question about Oklo, Cramer offered a blunt evaluation: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”
Cramer’s skepticism isn’t new. Earlier in January, he characterized Oklo as “not a commercial enterprise,” suggesting that while nuclear energy technology holds promise, established players like GE Vernova—with functioning commercial operations—represent superior investment opportunities compared to Oklo’s current position.
Financial Performance and Wall Street Reactions
Fundamentally, Oklo‘s latest quarterly filing revealed a per-share loss of $0.27, falling short of the analyst consensus forecast of -$0.17 by a notable $0.10 margin.
Despite continued optimism from the analyst community overall, price projections have undergone considerable revision. UBS reduced its target from $95 to $60 while assigning a neutral rating. Needham slashed expectations from $135 to $73, and Canaccord lowered its target from $175 to $125. Cantor Fitzgerald maintained its overweight designation with a $122 objective.
Currently, the consensus analyst price target stands at $84.30, accompanied by a “Moderate Buy” rating. The breakdown includes two Strong Buy recommendations, nine Buy ratings, six Hold opinions, and two Sell calls.
Oklo shares have traded in a 12-month range between $17.42 and $193.84. The stock’s 50-day moving average currently sits at $64.62, while the 200-day moving average stands at $93.16.


